HOTH News and Press, Hoth Therapeutics Inc. From 12/10/20

Immutep (IMMP) +132% after breast cancer trial shows promising survival data.Greenwich LifeSciences (GLSI) +57%.UTStarcom Holdings (UTSI) +50%.Panbela Therapeutics (PBLA) +46%.Leju Holdings (LEJU) +38%.SELLAS Life Sciences (SLS) +36%.ClearOne (CLRO) +35% to expand its footprint in M...

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit . The conference will be held November 17-19, 2020. ...

Hoth Therapeutics ([[HOTH]] +4.2%) has announced positive, proof-of-concept preclinical data for its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus ((CLE)), a chronic autoimmune skin disease.The study conducted by Jackson Laboratory in partnership with Zyl...

Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease The study was conducted by Jackson Laboratory in partnership with Zylö Therapeutic...

Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine Hoth Therapeutics expects key proof-of-concept data in Q4 2020 / Q1 2021 for its COVID-19 products it is currently developing PR Newswire NEW YORK, Nov. 2, ...

DBV Technologies S.A. (DBVT) +80% as EMA approves Viaskin Peanut application.Endurance International Group Holdings (EIGI) +61% on announcing agreement to be acquired by Clearlake Capital Group L.P.AnPac Bio-Medical Science (ANPC) +30% as its Chinese company secu...

U.S. Patent and Trademark Office has granted Hoth Therapeutics ([[HOTH]] +3.3%) patent No. 10,793,525 related to 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers. The patent expires on October 5, 2036.The potential therapeut...

Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic The USPTO issued the first of its kind patent, which provides IP protection through October 2036 PR Newswire NEW YORK, Oct. 20, 2020 ...

Hoth Therapeutics (HOTH) completes the first phase of the research in examining the ability of HT-003 in blocking acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.Initial data from the phase reports t...

Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2) Initial data reports one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003 PR Newswire NEW YORK,...